Japan prazosin market is estimated to decline at a CAGR of around -2.6% during the forecast period. Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Minipress in Japan and is used for the treatment of various diseases including BPH, heart failure, high blood pressure, and Raynaud’s syndrome. According to the American Heart Association in 2018, 43 million people in Japan were hypertensive, of which only 50% are treated, and about 25% are controlled at the target blood pressure (BP) level of <140/90 mm?Hg. The large number of hypertensive populations coupled with its poor control rate; hypertension is one of the leading causes of mortality in the country. In addition, in July 2019, the two companies announced a definitive agreement for combining Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/japan-prazosin-market
Japan prazosin market is segmented on the basis of application. Based on the application, the market is segmented into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for a significant share in the Japan prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.
The companies which are contributing to the growth of the Japan prazosin market include Ajinomoto Co., Inc., Standard Chem and Pharmaceuticals Co. Ltd., Sun Pharmaceuticals Industries Ltd., Merck KGaA, Mylan N.V., Pfizer Inc., and others. The market players are considerably contributing to the market by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
A full report of Japan Prazosin Market available @ https://www.omrglobal.com/industry-reports/japan-prazosin-market
Japan Prazosin Market Segmentation
By Application
- Cardiovascular Disease( CVD)
- Neurological Syndromes
- Prostate Disorders
- Kidney Disorders
Company Profiles
- Ajinomoto Co., Inc.
- Johnlee Pharmaceuticals Pvt. Ltd.
- Merck KGaA
- Pfizer Inc.
- R&D Systems Inc.
- Renata Ltd.
- Mylan N.V.
- Standard Chem and Pharmaceuticals Co. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
